Cargando…

Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings

Dopamine D2 receptor agonists represent a first line treatment option in young patients with signs and symptoms of idiopathic Parkinson's disease. An association between the use of D2 receptor agonists in Parkinson's disease patients and heart failure has been reported. The identification...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abou Farha, Khalid, Baljé-Volkers, Corine, Tamminga, Wim, den Daas, Izaak, van Os, Sandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920609/ https://www.ncbi.nlm.nih.gov/pubmed/24587918 http://dx.doi.org/10.1155/2014/956353

Ejemplares similares

Metabotropic Glutamate Receptor 5 Negative Modulation in Phase I Clinical Trial: Potential Impact of Circadian Rhythm on the Neuropsychiatric Adverse Reactions—Do Hallucinations Matter?
por: Abou Farha, Khalid, et al.
Publicado: (2014)

1575 A 28-day high-dose safety and pharmacokinetics study of raltegravir in healthy subjects
por: Krishna, Rajesh, et al.
Publicado: (2014)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Altered Pain Processing Associated with Administration of Dopamine Agonist and Antagonist in Healthy Volunteers
por: Martin, Sarah L., et al.
Publicado: (2022)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Prevalence of hypersexual behavior in Parkinson’s disease patients: Not restricted to males and dopamine agonist use
por: Cooper, Christine A, et al.
Publicado: (2009)

Correlation of Plasma EGF with Striatal Dopamine Transporter Availability in Healthy Subjects
por: Pak, Kyoungjune, et al.
Publicado: (2017)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Impulse control disorders and dopamine agonists
por: Martins, D., et al.
Publicado: (2021)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

The effects of dopamine and dopamine receptor agonists on the phototransduction cascade of frog rods
por: Nikolaeva, Darya A., et al.
Publicado: (2019)

Effect of rs3910105 in the Synuclein Gene on Dopamine Transporter Availability in Healthy Subjects
por: Seo, Youngduk, et al.
Publicado: (2018)

The effects of dopamine receptor 1 and 2 agonists and antagonists on sexual and aggressive behaviors in male green anoles
por: Smith, Alexandra N., et al.
Publicado: (2017)

Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
por: Costa, M.L., et al.
Publicado: (2022)

Pathological gambling and dopamine agonists: A phenotype?
por: Pinder, Roger M
Publicado: (2007)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Non-ergot dopamine agonists and heart failure
por: Şener, Yusuf Ziya, et al.
Publicado: (2019)

Predictors of dopamine agonist resistance in prolactinoma patients
por: Vermeulen, Elle, et al.
Publicado: (2020)

Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting
por: van Rossum, Inge, et al.
Publicado: (2009)

The Acute Impact of Smoking One Cigarette on Cardiac Hemodynamic Parameters
por: Farha, Khalid Abou, et al.
Publicado: (2011)

Dopamine cross-sensitization between psychostimulant drugs and stress in healthy male volunteers
por: Booij, L, et al.
Publicado: (2016)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
por: Pogorelov, Vladimir M., et al.
Publicado: (2023)

Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness
por: Crockett, Stacey L., et al.
Publicado: (2019)

Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma
por: Takeno, Ayumu, et al.
Publicado: (2016)

A dopamine receptor genetic variant enhances perceptual speed in cognitive healthy subjects
por: Barral, Sandra, et al.
Publicado: (2017)

Publicity and reports of behavioral addictions associated with dopamine agonists
por: Gendreau, Katherine E., et al.
Publicado: (2016)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
por: Pivonello, Claudia, et al.
Publicado: (2022)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
por: Frazer, Monica, et al.
Publicado: (2022)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

Insulin sensitivity variations in apparently healthy Arab male subjects: correlation with insulin and C peptide
por: Suleiman, Noor, et al.
Publicado: (2021)

Evaluation of Biological Variation of Different Clinical Laboratory Analytes in the Blood of Healthy Subjects
por: Ali, Md. Akshad, et al.
Publicado: (2023)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
por: Babey, Muriel, et al.
Publicado: (2010)

Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
por: Ersche, Karen D., et al.
Publicado: (2010)

The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke
por: Gorgoraptis, Nikos, et al.
Publicado: (2012)

Could Dopamine Agonists Aid in Drug Development for Anorexia Nervosa?
por: Frank, Guido K. W.
Publicado: (2014)

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease
por: Castro, Ester Suárez, et al.
Publicado: (2016)

Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia
por: Hollingworth, Samantha A., et al.
Publicado: (2015)

Dopamine Agonists and Impulse Control Disorders: A Complex Association
por: Grall-Bronnec, Marie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fgihsk4umvigj5eovspai6v796